Clinical Trial Update: Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tetrahydrocannabinol as an adjunct to opioid agonist therapy for opioid use disorder; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Methadone (methadone)
• Tetrahydrocannabinol (delta-9-tetrahydrocannabinol)

Snippet

Sponsor: BC Centre on Substance Use | Conditions: Opioid Use Disorder, Methadone | Phase 2 | Status: RECRUITING